Roche Diagnostics Unveils Groundbreaking Endotrophin Assay for Nordic Bioscience's Research Purposes

Roche Diagnostics Launches Prototyping Endotrophin Assay



In a significant advancement for cardiovascular research, Roche Diagnostics has made its prototype assay for endotrophin (ETP) available at Nordic Bioscience's CLIA laboratory. This cutting-edge immunoassay quantitatively assesses the intact endotrophin hormone, consisting of 77 amino acids. This biomarker plays a crucial role during collagen type VI formation and has been linked to various health conditions, including fibrosis, inflammation, and adverse outcomes in cardiovascular, renal, and metabolic diseases.

The introduction of the endotrophin assay marks a milestone in the collaboration between Nordic Bioscience and Roche Diagnostics, following the earlier launch of the Elecsys® PRO-C3, which is CE-marked. The endotrophin biomarker has already been analyzed in more than 50,000 patients suffering from cardiorenal-metabolic diseases. Notably, elevated endotrophin levels have been correlated with higher mortality rates and adverse outcomes in patients with preserved ejection fraction heart failure (HFpEF). The FDA has acknowledged the potential of endotrophin in ongoing research as a promising clinical trial enrichment tool for HFpEF.

What makes endotrophin particularly valuable is its ability to evaluate fibro-inflammatory risk beyond conventional markers such as PREVENT and NT-proBNP. In chronic kidney disease, endotrophin levels significantly rise with disease progression, offering predictive insights into decreases in estimated glomerular filtration rate (eGFR). Variations in endotrophin levels are also reflective of changes in renal function, demonstrating its clinical relevance.

Beyond serving as a risk marker, studies utilizing Mendelian randomization have established a causal relationship between endotrophin and coronary artery disease. Gene knockout models have shown that inhibiting endotrophin protects against renal fibrosis and loss of kidney function, identifying CD44 as the receptor for this hormone.

Morten Karsdal, CEO of Nordic Bioscience, emphasizes the importance of endotrophin, stating, "Endotrophin could become the best biomarker for cardiorenal syndrome; however, its significance extends beyond being a mere biomarker—it represents a potential therapeutic target, akin to TNF-alpha."

As the medical community continues to explore the multifaceted implications of this biomarker, the collaboration between Nordic Bioscience and Roche Diagnostics showcases a commitment to improving patient outcomes through innovative research and technology. The potential application of the endotrophin assay in clinical settings heralds a new chapter in the evaluation and management of cardiovascular and renal health.

For those interested in further information about Nordic Bioscience and its pioneering work, visit their official website at Nordic Bioscience.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.